Start Time: 08:00 January 1, 0000 8:56 AM ET
PROCEPT BioRobotics Corporation (NASDAQ:PRCT)
Q1 2023 Earnings Conference Call
April 27, 2023, 08:00 AM ET
Company Participants
Reza Zadno - President and CEO
Kevin Waters - EVP and CFO
Matt Bacso - VP, IR and Business Operations
Conference Call Participants
Craig Bijou - Bank of America
Joshua Jennings - Cowen
Ryan Zimmerman - BTIG
Chris Pasquale - Nephron Research
Neil Chatterji - B. Riley
Richard Newitter - Truist
Nathan Treybeck - Wells Fargo
Matthew Mishan - KeyBanc
Operator
Good morning, and welcome to the PROCEPT BioRobotics First Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer session towards the end of the call today. As a reminder, this call is being recorded for replay purposes.
I would now like to turn the call over to Matt Bacso, Vice President, Investor Relations, for a few introductory comments.
Matt Bacso
Good morning and thank you for joining PROCEPT BioRobotics first quarter 2023 earnings conference call. Presenting on today's call are Reza Zadno, Chief Executive Officer; and Kevin Waters, Chief Financial Officer.
Before we begin, I'd like to remind listeners that statements made on this conference call that relate to future plans, events or performance are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. While these forward-looking statements are based on management's current expectations and beliefs, these statements are subject to several risks, uncertainties, assumptions and other factors that could cause results to differ materially from the expectations expressed on this conference call. These risks and uncertainties are disclosed in more detail in PROCEPT BioRobotics filings with the Securities and Exchange Commission, all of which are available online at www.sec.gov.
Listeners are cautioned to not place undue reliance on these forward-looking statements, which speak only as of today's date, April 27, 2023. Except as required by law, PROCEPT BioRobotics undertakes no obligation to update or revise any forward-looking statements to reflect new information, circumstances or unanticipated events that may arise.
With that, I'll now turn the call over to Reza.
Reza Zadno
Good morning and thank you for joining us. For today's call, I will provide opening comments and a business update followed by Kevin, who will provide additional details regarding our financial performance and 2023 guidance before opening the call to Q&A. Starting with our quarterly revenue results. We are pleased to report another strong quarter where our customers and patients continue to realize the significant clinical benefits of Aquablation therapy.